Roche’s Tecentriq Plus Avastin Combination Reduced the Risk of Cancer Returning in People with Certain Types of Early-Stage Liver Cancer in a Phase III Trial

The Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma at high risk of recurrence following surgery met the primary endpoint of recurrence-free survival.